Water Tower Hour Recap: OvaWatch Update
CEO and Director Nicole Sandford joined us on the Water Tower Hour to discuss the latest on OvaSuite, Aspira’s portfolio of non-invasive tests for the risk assessment of ovarian cancer, in addition to the opportunities for the product pipeline and biobank. Those interested can listen to this podcast on Apple Podcasts, Spotify, or on our website. Links are available in our full report. OvaWatch mass monitoring completes OvaSuite portfolio. With the recent launch of longitudinal or serial adnexal mass monitoring for OvaWatch, physicians and patients could assess ongoing malignancy risk for all women with a mass. Collaboration opportunities for biobank. Aspira completed a full inventory of its biobank, identifying about 70K patient samples, which would be available for secondary research and potential collaboration opportunities. The biobank is a significant competitive advantage in developing solutions for ovarian cancer and other gynecologic diseases. Changing the care pathway system for ovarian cancer. Aspira is helping physicians feel more comfortable with adnexal mass management through two data publications around premature surgical interventions and OvaWatch longitudinal monitoring. The papers also provide compelling cost savings evidence for the payer community. Aspira has made significant progress in securing Medicaid and commercial coverage across the country. Strong return to growth in 2Q24. OvaWatch volume grew more than 20% sequentially over last quarter, using a smaller, more focused field sales team and refreshed messaging to physicians around OvaWatch and mass monitoring. Aspira sees a much larger market opportunity of 2-4 million tests a year for the complete OvaSuite portfolio, with OvaWatch driving the majority of the volume. Endometriosis test products progress in pipeline. EndoCheck is in validation steps using Aspira’s clinical samples in identifying endometrioma, with the company determining the best fit in clinical care pathway. EndoMDx aims to detect broader types of endometriosis using miRNA signatures in collaboration with the Dana Farber Cancer Institute. Aspira is a finalist for an ARPA-H grant based on the White House Initiative for Women’s Health for EndoMDx and OvaMDx research.
Water Tower Research is built on the foundation of democratizing information flow. We bridge the growing information gap between companies and investors through our investor engagement strategies and open-access research platform.
Our research analysts are Wall Street veterans with the experience and knowledge to work with companies and investors in tandem. We provide access to the information and content that anchors the due diligence process for both professional money managers and individual investors. We leverage traditional research distribution channels and the best of modern digital strategies and tactics to amplify this information flow globally to engage all categories of investors and stakeholders.
Information flow is the foundation for creating investor awareness, knowledge, and engagement. Our mission is to help companies and investors have the tools they need and achieve their goals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.